OTC NSAID Use in Patients With OA and CV Disease

Slides:

Advertisements

Similar presentations

Update in Prescribing and therapeutics: NSAID’s in Emergency Medicine.

Advertisements

Canadian Cardiovascular Society Antiplatelet Guidelines

Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 18 Nonopioid Analgesics: Nonsteroidal Anti-Inflammatory Drugs.

OTC NSAIDs AND NEPHROTOXICITY Juan Carlos Pelayo, M. D

CHAPTER © 2012 The McGraw-Hill Companies, Inc. All rights reserved. 20 Nonopioid Analgesics, Nonsteroidal Antiinflammatories, and Antigout Drugs.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting April 12, 2007 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Nonprescription Drugs Advisory Committee Meeting Charles J. Ganley, M.D. Division of OTC Drug Products September 20, 2002.

Canadian Cardiovascular Society Antiplatelet Guidelines

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

Introduction to Direct-to-Consumer Genetic Testing

The Effect of Intra-Articular Steroids on Cartilage in Knee Osteoarthritis.

Selection of NSAIDs for Osteoarthritis

Calcium Deficiency.

New Guidelines to Prevent SCD: What You Need to Know

This program will include a discussion of off-label treatment not approved by the FDA for use in the United States.

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

Gout Management.

Maximizing Medical Management of Knee Osteoarthritis

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Optimizing Therapy for Osteoarthritis

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

A CASE CHALLENGE IN HFrEF:

Cholesteryl Ester Transfer Protein Inhibitors

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Update on NSAID Use:.

Drug used within 3 months of index date Adjusted odds ratio* p

Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.

What Do We Know About LDL-C?

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Blood pressure control: dependence on adherence

An Update on PCSK9 Inhibitors

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

The future of urate-lowering strategies for gout

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

Understanding PAD.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Avoiding Opioid Overuse: Guideline-Based Management of Osteoarthritis

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

A PCP's Guide to Dyslipidemia

Radical New Concepts in Lipid Management

Aspirin in Cardioprevention:

Atrial Fibrillation.

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

Aspirin and Cardioprevention in 2018

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Factor Xa Inhibitors in PAD

SLE and Cardiovascular Risk

CAD/PAD in Primary Care

Case 1 Presentation Case 1 (cont) Assessment and Recommendations.

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Antithrombotic Therapy in PAD

Update on OTC Pain Relievers for Osteoarthritis

Factor Xa Inhibitors in Coronary Artery Disease

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Treating Osteoarthritis

Prioritizing Prevention of HPV-Related Disease

Managing Pain in the 21st Century

Selecting Treatment Approaches in Hemophilia

An Update on PCSK9 Inhibitors

Addressing Cardiovascular Events:

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Optimizing Treatment of Refractory Gout

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Expert Perspectives.

Non opioids pain management

Translating Data From Trial to Practice

Presentation transcript:

OTC NSAID Use in Patients With OA and CV Disease

Osteoarthritis Scope of Disease

NSAID Use in the United States

NSAID Risks

NSAIDs and Cardiovascular Risk

FDA Drug Safety Communication NSAID Use and CV Risk

Variables Determining NSAID CV Risk

Cyclooxygenase

Cardiovascular Syndromes Related to NSAID Use

CNT Collaboration

Major Vascular Event Risk Comparisons

Ibuprofen Blocks Aspirin

Cardioprotective Effect of Aspirin Inhibited by Ibuprofen

American Association of Orthopedic Surgery (AAOS) Recommendations for Management of OA

AAOS Recommendations

AAOS Recommendations (cont)

ACR Nonpharmacologic Recommendations for OA

ACR Pharmacologic Recommendations for OA

ACR Recommendations Selecting an NSAID

ACR Recommendations

Systematic Review of 16 Guidelines

Summary: Safe Use of NSAIDs in Patients With CV Disease

Abbreviations

Abbreviations (cont)